EUVIMEDEUVIMED entdecken
Crossref

Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy

Toshifumi Tada iD, Masayuki Kurosaki, Hidenori Toyoda iD, Nobuharu Tamaki, Yutaka Yasui, Shinichiro Nakamura, Nami Mori, Keiji Tsuji, Hironori Ochi, Takehiro Akahane, Haruhiko Kobashi, Hideki Fujii und 22 weitere

Liver International · 2024

DOI: 10.1111/liv.16093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Toshifumi Tada und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Sustained Virologic Response, Propensity Score. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Grant-in-Aid from the Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The impact of hepatitis C virus (HCV) eradication via direct‐acting antiviral (DAA) therapy on overall mortality, particularly non‐liver‐related mortality, is understudied.

Methods

We recruited 4180 patients with chronic HCV infection who achieved sustained virological response (SVR) (HCV eradication) through DAA therapy ( n = 2501, SVR group) or who did not receive antiviral therapy ( n = 1679, non‐SVR group); 1236 from each group were chosen using propensity score matching. Causes of death and all‐cause mortality, including non‐liver‐related diseases, were investigated.

Results

Of the 4180 patients, 592 died during the follow‐up period. In the SVR group, the mortality rates from liver‐related and non‐liver‐related diseases were 16.5% and 83.5%, respectively. Compared to the non‐SVR group, mortality rates from liver‐related and non‐liver‐related diseases were 50.1% and 49.9%, respectively ( p < .001). In non‐cirrhotic patients, multivariable analysis revealed that SVR was an independent factor associated with both liver‐related (hazard ratio [HR], .251; 95% confidence interval [CI], .092–.686) and non‐liver‐related (HR, .641; 95% CI, .415–.990) mortalities. In cirrhotic patients, multivariable analysis revealed that SVR remained an independent factor significantly associated with liver‐related mortality (HR, .151; 95% CI, .081–.279). In propensity score‐matched patients, the eradication of HCV (SVR group) decreased both liver‐related ( p < .001) and non‐liver‐related mortality ( p = .008) rates compared to persistent HCV infection (non‐SVR group).

Conclusions

The elimination of HCV via DAA therapy reduced not only liver‐related mortality but also non‐liver‐related mortality in patients with chronic HCV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicAntiviral AgentsSustained Virologic ResponsePropensity ScoreHumansFemaleMaleMiddle AgedAgedCause of DeathRetrospective StudiesHepacivirusMultivariate AnalysisAdultLiver CirrhosisProportional Hazards Models

Stichwörter der Autor:innen

direct‐acting antiviralhepatitis C virusliver‐related mortalitynon‐liver‐related mortalitysustained virological response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
  • Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
  • Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Department of Gastroenterology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Japan.

ORCID-Profile: Toshifumi Tada, Hidenori Toyoda, Michiko Nonogi, Satoshi Yasuda, Takashi Kumada

Förderung

  • Grant-in-Aid from the Japan Agency for Medical Research and Development

Zitieren

APA

Tada, T., Kurosaki, M., Toyoda, H., Tamaki, N., Yasui, Y., Nakamura, S., Mori, N., Tsuji, K., Ochi, H., Akahane, T., Kobashi, H., Fujii, H., Marusawa, H., Kondo, M., Urawa, N., Yoshida, H., Uchida, Y., Morita, A., Hasebe, C., …, & Izumi, N. (2024). Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy. Liver International. https://doi.org/10.1111/liv.16093

Vancouver

Tada T, Kurosaki M, Toyoda H, Tamaki N, Yasui Y, Nakamura S, et al. Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy. Liver International. 2024. doi:10.1111/liv.16093

BibTeX
@article{Tada2024,
  author = {Tada, Toshifumi and Kurosaki, Masayuki and Toyoda, Hidenori and Tamaki, Nobuharu and Yasui, Yutaka and Nakamura, Shinichiro and Mori, Nami and Tsuji, Keiji and Ochi, Hironori and Akahane, Takehiro and Kobashi, Haruhiko and Fujii, Hideki and Marusawa, Hiroyuki and Kondo, Masahiko and Urawa, Naohito and Yoshida, Hideo and Uchida, Yasushi and Morita, Atsuhiro and Hasebe, Chitomi and Mitsuda, Akeri and Ogawa, Chikara and Narita, Ryoichi and Kubotsu, Yoshihito and Matsushita, Tomomichi and Shigeno, Masaya and Okamoto, Eisuke and Okada, Kazuhiko and Kasai, Toyotaka and Ishii, Toru and Nonogi, Michiko and Yasuda, Satoshi and Koshiyama, Yuichi and Kumada, Takashi and Izumi, Namiki},
  title = {Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.16093}
}
Kostenlos starten →